Psychedelic therapy stocks are surging Monday after President Donald Trump signed an executive order to accelerate research and access to these treatments. The move has sent shares of companies involved in psychedelic-related therapies climbing in premarket trading, signaling investor optimism about the sector's future.

Psychedelic medicine has been gaining traction as a potential treatment for mental health conditions like depression, PTSD, and anxiety. Companies in this space have been working to develop FDA-approved therapies using substances such as psilocybin and MDMA. The executive order could remove regulatory hurdles that have slowed clinical trials and market entry.

This development comes as the psychedelic medicine industry has been attracting significant investment interest. Major pharmaceutical companies and venture capital firms have been pouring money into research and development. The sector's growth potential has been compared to the early days of cannabis legalization, with some analysts predicting substantial market expansion if regulatory barriers fall.